Harmonization International Bone Sarcoma Consortium (HIBiSCus)
Publication Policy
Last updated January 21, 2022

This policy has two (2) parts:
• Projects initiating outside of HIBiSCus Work Groups (investigator initiated)
• Projects initiating from a HIBiSCus Work Group

FOR PROJECTS INITIATING OUTSIDE OF HIBiSCus WORK GROUPS (investigator initiated)

The HIBiSCus Executive Committee Co-Chairs will route all project requests to all members of the Executive Committee for review.

Project review: All projects will be routed to the HIBiSCus Executive Committee for review. The Committee may approve with comments, return for revisions, or reject the proposal.

Project team: Once the project request is approved, the HIBiSCus Executive Committee will make the following recommendations regarding the project team:
• If patients in the study have been contributed by a cooperative group, then the HIBiSCus Executive Committee will ask the cooperative group chair to nominate an individual who will be an active member of the research team.
• Involvement of young investigators will be very strongly encouraged.
• The HIBiSCus Executive Committee will determine if the project requires additional experts to be added to the team. This might include (a) individual(s) who played a key role in generating the data to be actively involved in the analysis of the data and preparing the study abstracts and manuscripts or (b) “specialty” experts (for example, pathologists, cytogeneticists, radiologists, etc.).
• Based on the extensive work of the cooperative group statisticians, the HIBiSCus Executive Committee and cooperative group chairs will be invited to nominate a statistician to participate in the work and be included on the manuscript (for cooperative groups that contributed patients to be included in the proposed project).
• When applicable, authors should consider the option to include additional co-authors under the name Pediatric Cancer Data Commons (PCDC) Harmonization International Bone Sarcoma Consortium (HIBiSCus) contributors to represent additional significant contributors.

Authorship of Abstracts and Manuscripts
• Nominated individuals MUST be actively and intellectually involved in the project to be a co-author.
• It is anticipated that collaboration with international experts will greatly enhance the research conducted with these data.
• Authorship will be determined by the primary investigators for this project request, in alignment with the above rules.
• Co-authorship will only be warranted for collaborators who meet the ICMJE recommendations for authorship.
• The Co-Chairs of HIBiSCus are not automatically co-authors; they will be co-authors only if they have been actively and intellectually involved in the project.
• To support the training goals of HIBiSCus, (full) professors are asked to consider co-senior authorship or not being senior author.
• Data will not be released to the investigators until cooperative group representatives have been identified.
Acknowledgments:

This research would not be possible without the HIBiSCus data contributors who have shared their data.

The Harmonization International Bone Sarcoma Consortium and the Pediatric Cancer Data Commons are supported in part by the Rally Foundation for Childhood Cancer Research and the St Baldrick’s Foundation. This work is made possible through the efforts of Children’s Oncology Group (COG), Cooperative Ewing Sarcoma Study Group (CESS) of Gesellschaft für pädiatrische Onkologie und Hämatologie (GPOH), Cooperative Osteosarcoma Study Group (COSS) of Gesellschaft für pädiatrische Onkologie und Hämatologie (GPOH), Euro Ewing Consortium (EEC), French Bone Sarcoma Group GROUPOS (SFCE, GSF-GETO, UNICANCER), Grupo América Latina de Oncología Pediátrica (GALOP), Italian Sarcoma Group (ISG), National Cancer Research Institute Sarcoma Clinical Studies Group (NCRI), Scandinavian Sarcoma Group (SSG), Spanish Sarcoma Group (GEIS), and the funders of the clinical trials from which these data are derived.

Information: The authors must inform the HIBiSCuS Executive Committee when an abstract or manuscript arising from the research project is submitted.

Review: The HIBiSCus Executive Committee will review all abstracts and manuscripts prior to submission for publication to ensure proper acknowledgments are included. Abstract review time period is five (5) business days and manuscript review time period is ten (10) business days.
FOR PROJECTS INITIATING FROM A HIBiSCus WORK GROUP

Project and project team: The HIBiSCus Executive Committee will make the following recommendations regarding the project and the project team:

1. All HIBiSCus Work Groups will submit project and manuscript ideas to the HIBiSCus Executive Committee, including the topic, lead author, and identified co-authors.
   a. The Executive Committee will ensure appropriate and balanced representation from all cooperative groups.
   b. For projects and manuscripts that cross disciplines, the initiating Work Group lead will contact the Work Group lead(s) of the additional discipline(s) for a collaborator recommendation. Consideration will be given to expertise and cooperative groups. The HIBiSCus Executive Committee Co-Chairs may be consulted for recommendations.

2. The HIBiSCus Executive Committee will review and approve the ideas and the author lists.

3. The HIBiSCus Executive Committee will maintain a list of planned projects and manuscripts identified by all HIBiSCus Work Groups.

4. When applicable, authors should consider the option to include additional co-authors under the name Pediatric Cancer Data Commons (PCDC) Harmonization International Bone Sarcoma Consortium (HIBiSCus) contributors to represent additional significant contributors.

Authorship of Abstracts and Manuscripts:

- Nominated individuals MUST be actively and intellectually involved in the project to be a co-author.
- It is anticipated that collaboration with international experts will greatly enhance the research conducted with these data.
- Authorship will be determined by the primary investigators for this project request, in alignment with the above rules.
- Co-authorship will only be warranted for collaborators who meet the ICMJE recommendations for authorship.
- The Co-Chairs of HIBiSCus are not automatically co-authors; they will be co-authors only if they have been actively and intellectually involved in the project.
- To support the training goals of HIBiSCus, (full) professors are asked to consider co-senior authorship or not being senior author.

Acknowledgments:

This research is presented on behalf of HIBiSCus and would not be possible without the HIBiSCus data contributors who have shared their data.

The Harmonization International Bone Sarcoma Consortium and the Pediatric Cancer Data Commons are supported in part by the Rally Foundation for Childhood Cancer Research and the St Baldrick’s Foundation. This work is made possible through the efforts of Children’s Oncology Group (COG), Cooperative Ewing Sarcoma Study Group (CESS) of Gesellschaft für pädiatrische Onkologie und Hämatologie (GPOH), Cooperative Osteosarcoma Study Group (COSS) of Gesellschaft für pädiatrische Onkologie und Hämatologie (GPOH), Euro Ewing Consortium (EEC), French Bone Sarcoma Group GROUPOS (SFCE, GSF-GETO, UNICANCER), Grupo América Latina de Oncologia Pediátrica (GALOP), Italian Sarcoma Group (ISG), National Cancer Research Institute Sarcoma Clinical Studies Group (NCRI), Scandinavian Sarcoma Group (SSG), and Spanish Sarcoma Group (GEIS).
Information: The authors must inform the HIBiSCuS Executive Committee when an abstract or manuscript arising from the research project is submitted.

Review: The HIBiSCuS Executive Committee will review all abstracts and manuscripts prior to submission for publication to ensure that

- Proper acknowledgments are included, and
- A consensus paper reflects a true consensus of the groups and not just the expert opinions of the work group authors. Feedback will be provided along with an indication that re-review is required or authors may proceed with submission.

Abstract review time period is five (5) business days and manuscript review time period is ten (10) business days.